Cargando…

Immune Checkpoint Inhibitors versus VEGF Targeted Therapy as Second Line Regimen in Advanced Hepatocellular Carcinoma (HCC): A Retrospective Study

Several targeted agents including multi-tyrosine kinase inhibitors (mTKIs) and immunotherapy (IO) agents have been approved for use beyond the frontline setting in patients with advanced hepatocellular carcinoma (HCC). Due to lack of prospective head-to-head comparative trials, there is no standardi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Saeed, Anwaar, Hildebrand, Hannah, Park, Robin, Al-Jumayli, Mohammed, Abbasi, Saqib, Melancon, Tina, Saeed, Azhar, Al-Rajabi, Raed, Kasi, Anup, Baranda, Joaquina, Williamson, Stephen, Sun, Weijing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7563439/ https://www.ncbi.nlm.nih.gov/pubmed/32824968 http://dx.doi.org/10.3390/jcm9092682

Ejemplares similares

Total Neoadjuvant Therapy vs Standard Therapy in Locally Advanced Rectal Cancer: A Systematic Review and Meta-analysis
por: Kasi, Anup, et al.
Publicado: (2020)

Clinical Outcome of Ampullary Carcinoma: Single Cancer Center Experience
por: Al-Jumayli, Mohammed, et al.
Publicado: (2019)

Association of Neutrophil, Platelet, and Lymphocyte Ratios with the Prognosis in Unresectable and Metastatic Pancreatic Cancer
por: Allen, Jessica, et al.
Publicado: (2020)

Real world outcomes in patients with neuroendocrine tumor receiving peptide receptor radionucleotide therapy
por: Hentzen, Stijn, et al.
Publicado: (2023)

Update on the Role of Poly (ADP-Ribose) Polymerase Inhibitors in the DNA Repair-Deficient Pancreatic Cancers: A Narrative Review
por: Kasi, Anup, et al.
Publicado: (2020)

Similar response rates and survival with PARP inhibitors for patients with solid tumors harboring somatic versus Germline BRCA mutations: a Meta-analysis and systematic review
por: Mohyuddin, Ghulam Rehman, et al.
Publicado: (2020)

Cabozantinib plus durvalumab in advanced gastroesophageal cancer and other gastrointestinal malignancies: Phase Ib CAMILLA trial results
por: Saeed, Anwaar, et al.
Publicado: (2023)

A phase II study of perioperative pembrolizumab plus mFOLFOX in patients with potentially resectable esophagus, gastroesophageal junction (GEJ), and stomach adenocarcinoma
por: Sun, Weijing, et al.
Publicado: (2023)

Immuno-Oncotherapeutic Approaches in Advanced Hepatocellular Carcinoma
por: Park, Robin, et al.
Publicado: (2020)

The integration of immune checkpoint inhibitors with VEGF targeted agents in advanced gastric and gastroesophageal adenocarcinoma: a review on the rationale and results of early phase trials
por: Saeed, Anwaar, et al.
Publicado: (2021)

Circulating Tumor Cell Subpopulations Predict Treatment Outcome in Pancreatic Ductal Adenocarcinoma (PDAC) Patients
por: Freed, Ian M., et al.
Publicado: (2023)

Clinical Evaluation of Ramucirumab for the Treatment of Hepatocellular Carcinoma (HCC): Place in Therapy
por: Choucair, Khalil, et al.
Publicado: (2021)

Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC
por: Sharma, Rohini, et al.
Publicado: (2022)

Hepatocellular carcinoma and immunotherapy: Beyond immune checkpoint inhibitors
por: Abushukair, Hassan Mohammed, et al.
Publicado: (2022)

A Multicenter, Open-Label, Phase I/II Study of FN-1501 in Patients with Advanced Solid Tumors
por: Richardson, Gary Edward, et al.
Publicado: (2023)

Genomic and Transcriptomic Predictors of Response to Immune Checkpoint Inhibitors in Melanoma Patients: A Machine Learning Approach
por: Ahmed, Yaman B., et al.
Publicado: (2022)

Unremitting chronic skin lesions: a case of delayed diagnosis of glucagonoma
por: Kawsar, Hameem I., et al.
Publicado: (2019)

Cancer-Associated Fibroblasts in Gastrointestinal Cancers: Unveiling Their Dynamic Roles in the Tumor Microenvironment
por: Al-Bzour, Noor N., et al.
Publicado: (2023)

Immune Checkpoint Inhibitors in the Treatment of HCC
por: Donisi, Clelia, et al.
Publicado: (2021)

Comparison of Efficacy of Systemic Therapies in Advanced Hepatocellular Carcinoma: Updated Systematic Review and Frequentist Network Meta-Analysis of Randomized Controlled Trials
por: Park, Robin, et al.
Publicado: (2021)

Anti-Inflammatory and Immune Properties of Polyunsaturated Fatty Acids (PUFAs) and Their Impact on Colorectal Cancer (CRC) Prevention and Treatment
por: Tojjari, Alireza, et al.
Publicado: (2023)

Immune Checkpoint Inhibitors: The Unexplored Landscape of Geriatric Oncology
por: Choucair, Khalil, et al.
Publicado: (2022)

Treatment-Related Adverse Events of Combination Immune Checkpoint Inhibitors: Systematic Review and Meta-Analysis
por: Park, Robin, et al.
Publicado: (2020)

Overcoming Immune Checkpoint Therapy Resistance with SHP2 Inhibition in Cancer and Immune Cells: A Review of the Literature and Novel Combinatorial Approaches
por: Tojjari, Alireza, et al.
Publicado: (2023)

Tumor Molecular and Microenvironment Characteristics in EBV-Associated Malignancies as Potential Therapeutic Targets: Focus on Gastric Cancer
por: Atri-Schuller, Aviva, et al.
Publicado: (2022)

Is obesity a risk factor in cancer patients with COVID-19?
por: Park, Robin, et al.
Publicado: (2021)

CAXII inhibitors: Potential sensitizers for immune checkpoint inhibitors in HCC treatment
por: Han, Rui, et al.
Publicado: (2023)

The role of VEGF in melanoma progression
por: Rajabi, Parvin, et al.
Publicado: (2012)

The Optimization of an Anti-VEGF Therapeutic Regimen for Neovascular Glaucoma
por: Bai, Ling, et al.
Publicado: (2022)

Non-Operative Management of Iatrogenic Intraperitoneal Bladder Injury Following a Cesarean Section
por: Albukhari, Saeed N, et al.
Publicado: (2021)

Prognostic value of tumor mutation burden (TMB) and INDEL burden (IDB) in cancer: current view and clinical applications
por: Saeed, Anwaar, et al.
Publicado: (2020)

Sex-bias in COVID-19-associated illness severity and mortality in cancer patients: A systematic review and meta-analysis
por: Park, Robin, et al.
Publicado: (2020)

Understanding immune perspectives and options for the use of checkpoint immunotherapy in HCC post liver transplant
por: Anugwom, Chimaobi M., et al.
Publicado: (2022)

The association between antibiotic use and outcomes of HCC patients treated with immune checkpoint inhibitors
por: Zhang, Lilong, et al.
Publicado: (2022)

Impact and Novel Perspective of Immune Checkpoint Inhibitors in Patients with Early and Intermediate Stage HCC
por: Marzi, Luca, et al.
Publicado: (2022)

A Meta-Analysis to Assess the Efficacy of HER2-Targeted Treatment Regimens in HER2-Positive Metastatic Colorectal Cancer (mCRC)
por: Chitkara, Akshit, et al.
Publicado: (2023)

The Crosstalk between Microbiome and Immunotherapeutics: Myth or Reality
por: Tojjari, Alireza, et al.
Publicado: (2022)

Reasons for not performing surface ablation refractive surgery in Saudi population
por: Alsulami, Raed, et al.
Publicado: (2020)

Is Time to Reach EDSS 6.0 Faster in Patients with Late-Onset versus Young-Onset Multiple Sclerosis?
por: Alroughani, Raed, et al.
Publicado: (2016)

Recent Advances and Future Prospects in Immune Checkpoint (ICI)-Based Combination Therapy for Advanced HCC
por: Dong, Yawen, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_qvee1js649j1ok3667a5rhq6bk